文献速递中毒与环境急症重症综合管理与镇静镇痛

2011-2017年美国毒物控制中心报告的卡痛叶暴露

Kratom exposures reported to United States poison control centers: 2011-2017.
PubMed 文献 · Clin Toxicol (Phila) · 2019-02-20
一句话结论2011-2017年美国毒物中心报告1807例卡痛叶暴露,65.0%发生在2016-2017年,多物质暴露显著增加入院和严重结局风险。

本研究分析2011-2017年美国毒物控制中心国家毒物数据系统报告的卡痛叶暴露。共1807例,65.0%发生在2016-2017年,88.9%为成人≥20岁,70.8%为男性,86.1%发生在住所,74.3%为有意暴露。一线卡痛叶暴露中31.8%入院,51.9%为严重医学结局;多物质暴露较单物质暴露入院OR 2.80(95%CI 2.21-3.55)、严重结局OR 2.25(95%CI 1.77-2.85)。共11例死亡与卡痛叶暴露相关,其中2例仅暴露于卡痛叶。

要点

  • 2011-2017年美国毒物中心共报告1807例卡痛叶暴露,65.0%集中在2016-2017年。
  • 一线卡痛叶暴露中31.8%入院、51.9%为严重医学结局;多物质暴露较单物质暴露入院OR 2.80(95%CI 2.21-3.55)。
  • 仅卡痛叶暴露中86.1%出现至少一种临床效应,最常见为激越/易激惹(22.9%)和心动过速(21.4%)。
  • 共11例死亡与卡痛叶暴露相关,其中2例仅暴露于卡痛叶。
  • 报告7例新生儿暴露,其中5例出现戒断。

适用人群与场景

  • 2011-2017年向美国毒物控制中心报告的卡痛叶(Mitragyna speciosa)暴露者,88.9%为成人≥20岁,70.8%为男性,86.1%发生在住所。

红旗征与不能漏的情况

  • 多物质暴露较单物质暴露入院OR 2.80(95%CI 2.21-3.55)、严重医学结局OR 2.25(95%CI 1.77-2.85)。
  • 仅卡痛叶暴露中86.1%出现至少一种临床效应,最常见为激越/易激惹(22.9%)和心动过速(21.4%)。
  • 共11例死亡与卡痛叶暴露相关,其中2例仅暴露于卡痛叶。
  • 7例新生儿暴露中5例出现戒断。

研究设计与关键结果

  • 研究类型为美国毒物控制中心国家毒物数据系统(NPDS)2011-2017年暴露数据分析,共1807例卡痛叶暴露。
  • 65.0%的暴露发生在2016-2017年;74.3%为有意暴露。
  • 一线卡痛叶暴露中31.8%收入医疗机构,51.9%为严重医学结局。
  • 多物质暴露较单物质暴露入院OR 2.80(95%CI 2.21-3.55),严重医学结局OR 2.25(95%CI 1.77-2.85)。
  • 仅卡痛叶暴露中86.1%出现至少一种临床效应,最常见为激越/易激惹(22.9%)和心动过速(21.4%)。
  • 共11例死亡与卡痛叶暴露相关,其中2例仅暴露于卡痛叶;7例新生儿暴露中5例出现戒断。

证据类型、等级与局限

  • 证据类型:基于美国毒物控制中心国家毒物数据系统(NPDS)的暴露数据分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为应教育选择使用卡痛叶的个体认识其潜在风险,包括与其他物质合用的危险。
  • 作者认为增加对卡痛叶产品的监管有助于保证产品质量和安全。
  • 作者认为需要更多研究来明确人体对卡痛叶的反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Context: Kratom, or Mitragyna speciosa, is a plant indigenous to Southeast Asia that has gained national attention in the United States for its increased use in the self-management of opioid withdrawal and pain, as well as for concerns about its safety. Methods: This study analyzes exposures to kratom reported to poison control centers (PCCs) in the United States during 2011-2017 from the National Poison Data System (NPDS). Discussion: From 2011 through 2017, 1807 kratom exposures were reported to United States PCCs. Almost two-thirds (65.0%) of these exposures occurred during 2016-2017. Most exposures occurred among adults ≥20 years (88.9%), males (70.8%), at a residence (86.1%), and were intentional (74.3%). Among first-ranked kratom exposures, 31.8% resulted in admission to a health care facility (HCF) and 51.9% in a serious medical outcome. Multiple-substance exposures were associated with greater odds of admission to a HCF (OR: 2.80; 95% CI: 2.21-3.55) and a serious medical outcome (OR: 2.25; 95% CI: 1.77-2.85) compared with single-substance exposures. There were 11 deaths associated with kratom exposure, including two that occurred after exposure to kratom only. Among kratom-only exposures, 86.1% resulted in one or more clinical effects. The most common clinical effects were agitation/irritability (22.9%) and tachycardia (21.4%). There were seven neonatal exposures, including five experiencing withdrawal. Conclusions: Kratom is associated with a variety of serious medical outcomes, especially when used with other substances. More research is needed to define the human response to kratom. Increased regulation of kratom products would help guarantee product quality and safety. Individuals who choose to use kratom should be educated about its potential risks, including the dangers of using it in combination with other substances.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Post S, Spiller HA, Chounthirath T, et al. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol (Phila). 2019. PMID: 30786220. doi:10.1080/15563650.2019.1569236

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。